A three months phase IIb study of MP1032 with higher doses in patients with moderate-to-severe chronic plaque psoriasis

Trial Profile

A three months phase IIb study of MP1032 with higher doses in patients with moderate-to-severe chronic plaque psoriasis

Recruiting
Phase of Trial: Phase II

Latest Information Update: 07 Mar 2018

At a glance

  • Drugs MP 1032 (Primary)
  • Indications Plaque psoriasis
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 07 Mar 2018 Status changed from planning to recruiting, according to a MetrioPharm media release.
    • 06 Mar 2018 According to a MetrioPharm media release, the company announces first dosing of first patient in this study.
    • 16 Mar 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top